Paratek Pharmaceuticals Announces Modification Of BARDA Contract To Advance The Development Of NUZYRA For Post-Exposure Prophylaxis And Treatment Of Pulmonary Anthrax
Portfolio Pulse from Happy Mohamed
Paratek Pharmaceuticals has announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA). The modification provides new development milestones for the next procurement of NUZYRA, a treatment for pulmonary anthrax. The next procurement will be split into two equal parts based on the achievement of specific development milestones. The first procurement will be triggered by positive data from a dose-ranging efficacy study in 2024. The second procurement will be triggered by positive data from two studies in 2024. The final procurement will be triggered by Paratek's receipt of sNDA approval from the FDA for the treatment of inhalation anthrax.
July 10, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Paratek Pharmaceuticals' contract modification with BARDA for the development of NUZYRA could potentially lead to increased revenues in the future. The next procurement is expected in 2024, which could provide a positive impact on the company's stock.
The contract modification provides new development milestones for the next procurement of NUZYRA, a treatment for pulmonary anthrax. This could potentially lead to increased revenues for Paratek Pharmaceuticals in the future, which could have a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100